English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 14 November 2022, 11:30 HKT/SGT
Share:
    

Source: Airlangga University
InaVac gets emergency approval from BPOM

Surabaya, East Java, Indonesia, Nov 14, 2022 - (ACN Newswire) - The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair).

InaVac, COVID-19 vaccine, is developed by the University of Airlangga in Surabaya, East Java Province. (ANTARA/HO-BPBRIN Unair)

"InaVac has obtained emergency use authorization from BPOM and will be mass-produced," the rector of Unair, Prof. Moh. Nasih, said on the sidelines of the campus' dies natalis (anniversary) on Wednesday.

The vaccine, which can be used to prevent a COVID-19 infection, has been made using an inactivated virus, which means, a virus that cannot reproduce and cause disease.

InaVac has been approved for use as a primary vaccine for people aged 18 and above for boosting immunity levels.

According to Nasih, the vaccine was developed as part of an effort by the university to significantly contribute to and impact the health sector.

Following the provision of EUA from BPOM, he expressed his gratitude to various stakeholders that have supported the development of the vaccine.

"Thank you to the Ministry of Health for providing support in the form of large amounts of funding; the provincial government has also provided extraordinary support," he remarked.

"Dr. Soetomo Hospital has also been very supportive. Equally important has been the role of Unair researchers who worked hard for this," he added.

Former state-owned enterprises minister Dahlan Iskan also expressed his pleasure over the completion of the domestically-made COVID-19 vaccine.

"I am happy because Unair has processed this vaccine to completion. How this vaccine was successfully launched, how to find people who want to undergo the vaccine. Finding people who are willing to be clinically tested is extremely difficult but Unair managed to finish it," he said.

It is hoped that after InaVac, more vaccines will be produced through continued research and development so that they can answer future challenges and problems.

Unair is currently developing a booster vaccine and a COVID-19 vaccine for children.

"The news about vaccines has been very encouraging; hopefully, later booster vaccines and children can be produced," he said.

For further information, please visit: https://www.unair.ac.id/

Written by: Abdul Hakim, Yashinta Difa, Editor: Fardah Assegaf (c) ANTARA 2022

Topic: Press release summary
Source: Airlangga University

Sectors: BioTech, Healthcare & Pharm, Government, MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
ACROMETA Group Appoints Veteran Investor Mr. Levin Lee as Executive Chairman  
Feb 1, 2023 16:00 HKT/SGT
Compact CO2 Capture System Receives "Awards for Excellence" at the 2022 Nikkei Excellent Products and Services Awards  
Wednesday, February 1, 2023 3:52:00 PM
RHTLaw Asia strengthens Litigation & Dispute Resolution Practice through merger with ChangAroth Chambers  
Feb 1, 2023 14:30 HKT/SGT
GenTwo Continues Growth Story, New Inflows of Over US$1 Billion  
Feb 1, 2023 14:00 HKT/SGT
Society Pass (Nasdaq: SOPA) Engages ThinkEquity to Facilitate Stock Repurchase Program of Up to US$2 Million Commencing on 01 February 2023  
Feb 1, 2023 14:00 HKT/SGT
Truescope Acquires US Firm Universal Information Services  
Feb 1, 2023 12:30 HKT/SGT
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China  
Feb 1, 2023 10:00 HKT/SGT
Fujitsu outlines vision for secure and sustainable network technologies at MWC Barcelona 2023
FP
  
Wednesday, February 1, 2023 9:53:00 AM
Job Market in Malaysia Thrives with 65% Increase in Retail Hiring: foundit Insights Tracker  
Feb 1, 2023 09:00 HKT/SGT
Premiere of New Mazda CX-90 Crossover SUV  
Wednesday, February 1, 2023 8:00:00 AM
More Press release >>
 Events:
More events >>
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575